Patent · US Active

Method for the early diagnosis of clinically latent placental insufficiency associated with defective placental maturation

US9568485B2 · kind B2 · utility

0Cited by

0References

19Claims

0Family size

Assignee

Universitätsmedizin der Johannes Gutenberg-Universität Mainz · DE

Inventors

Larissa Seidmann · Mainz, DE
Charles James Kirkpatrick · Dexheim, DE

Key dates

Filing date	Jul 20, 2012
Grant date	Feb 14, 2017
Priority date	—
Expiry date	Jan 14, 2033

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12Q2600/158
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to a method for the early diagnosis of a clinically latent placental insufficiency in pathological placental maturation, and the prophylaxis of an intrauterine fetal hypoxia/asphyxia at the due date or after a prolonged gestation, comprising determining the amount and/or the concentration of the biomarker prokineticin 1 (EG-VEGF) and/or its receptor PKR1 and/or PKR2 in a sample from the pregnant subject and/or the pregnancy. In a preferred embodiment, the invention is based on determining the ratio of the amount and/or the concentration of bFGF/PK1 as a measure of current functional condition and an indicator of latent clinical problems such as placental dysfunction resulting in fetal hypoxia.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.